Plasma Ceramides

Jeffrey W. Meeusen, Leslie J. Donato, Sandra C. Bryant, Linnea M. Baudhuin, Peter B. Berger, Allan S Jaffe

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective- Ceramides are sphingolipids involved with cellular signaling. Synthesis of ceramides occurs in all tissues. Ceramides accumulate within tissues and the blood plasma during metabolic dysfunction, dyslipidemia, and inflammation. Elevations of ceramides are predictive of cardiovascular mortality. We sought to verify the utility of plasma concentrations of 4 ceramides: N-palmitoyl-sphingosine [Cer(16:0)], N-stearoyl-sphingosine [Cer(18:0)], N-nervonoyl-sphingosine [Cer(24:1)], and N-lignoceroyl-sphingosine [Cer(24:0)] in predicting major adverse cardiovascular events in a diverse patient population referred for coronary angiography. Approach and Results- Plasma ceramides were measured in 495 participants before nonurgent coronary angiography. Coronary artery disease, defined as >50% stenosis in ≥1 coronary artery, was identified 265 (54%) cases. Ceramides were not significantly associated with coronary artery disease. Patients were followed for a combined primary end point of myocardial infarction, percutaneous intervention, coronary artery bypass, stroke, or death within 4 years. Ceramides were significantly predictive of outcomes after adjusting for age, sex, body mass index, hypertension, smoking, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, serum glucose, and family history of coronary artery disease. The fully adjusted per SD hazard ratios (95% confidence interval) were 1.50 (1.16-1.93) for Cer(16:0), 1.42 (1.11-1.83) for Cer(18:0), 1.43 (1.08-1.89) for Cer(24:1), and 1.58 (1.22-2.04) for the ceramide risk score. Conclusions- Elevated plasma concentrations of ceramides are independently associated with major adverse cardiovascular events in patients with and without coronary artery disease.

Original languageEnglish (US)
Pages (from-to)1933-1939
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume38
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Ceramides
Sphingosine
Coronary Artery Disease
Coronary Angiography
Sphingolipids
Dyslipidemias
Coronary Artery Bypass
LDL Cholesterol
HDL Cholesterol
Coronary Vessels
Pathologic Constriction
Triglycerides
Body Mass Index
Smoking
Stroke
Myocardial Infarction
Confidence Intervals
Hypertension
Inflammation
Glucose

Keywords

  • atherosclerosis
  • chemistry
  • heart diseases
  • humans
  • laboratories
  • metabolomics
  • risk

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Meeusen, J. W., Donato, L. J., Bryant, S. C., Baudhuin, L. M., Berger, P. B., & Jaffe, A. S. (2018). Plasma Ceramides. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(8), 1933-1939. https://doi.org/10.1161/ATVBAHA.118.311199

Plasma Ceramides. / Meeusen, Jeffrey W.; Donato, Leslie J.; Bryant, Sandra C.; Baudhuin, Linnea M.; Berger, Peter B.; Jaffe, Allan S.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 38, No. 8, 01.08.2018, p. 1933-1939.

Research output: Contribution to journalArticle

Meeusen, JW, Donato, LJ, Bryant, SC, Baudhuin, LM, Berger, PB & Jaffe, AS 2018, 'Plasma Ceramides', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 38, no. 8, pp. 1933-1939. https://doi.org/10.1161/ATVBAHA.118.311199
Meeusen JW, Donato LJ, Bryant SC, Baudhuin LM, Berger PB, Jaffe AS. Plasma Ceramides. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018 Aug 1;38(8):1933-1939. https://doi.org/10.1161/ATVBAHA.118.311199
Meeusen, Jeffrey W. ; Donato, Leslie J. ; Bryant, Sandra C. ; Baudhuin, Linnea M. ; Berger, Peter B. ; Jaffe, Allan S. / Plasma Ceramides. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2018 ; Vol. 38, No. 8. pp. 1933-1939.
@article{07b5261b1c124d2a80e291a2d46a8ddd,
title = "Plasma Ceramides",
abstract = "Objective- Ceramides are sphingolipids involved with cellular signaling. Synthesis of ceramides occurs in all tissues. Ceramides accumulate within tissues and the blood plasma during metabolic dysfunction, dyslipidemia, and inflammation. Elevations of ceramides are predictive of cardiovascular mortality. We sought to verify the utility of plasma concentrations of 4 ceramides: N-palmitoyl-sphingosine [Cer(16:0)], N-stearoyl-sphingosine [Cer(18:0)], N-nervonoyl-sphingosine [Cer(24:1)], and N-lignoceroyl-sphingosine [Cer(24:0)] in predicting major adverse cardiovascular events in a diverse patient population referred for coronary angiography. Approach and Results- Plasma ceramides were measured in 495 participants before nonurgent coronary angiography. Coronary artery disease, defined as >50{\%} stenosis in ≥1 coronary artery, was identified 265 (54{\%}) cases. Ceramides were not significantly associated with coronary artery disease. Patients were followed for a combined primary end point of myocardial infarction, percutaneous intervention, coronary artery bypass, stroke, or death within 4 years. Ceramides were significantly predictive of outcomes after adjusting for age, sex, body mass index, hypertension, smoking, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, serum glucose, and family history of coronary artery disease. The fully adjusted per SD hazard ratios (95{\%} confidence interval) were 1.50 (1.16-1.93) for Cer(16:0), 1.42 (1.11-1.83) for Cer(18:0), 1.43 (1.08-1.89) for Cer(24:1), and 1.58 (1.22-2.04) for the ceramide risk score. Conclusions- Elevated plasma concentrations of ceramides are independently associated with major adverse cardiovascular events in patients with and without coronary artery disease.",
keywords = "atherosclerosis, chemistry, heart diseases, humans, laboratories, metabolomics, risk",
author = "Meeusen, {Jeffrey W.} and Donato, {Leslie J.} and Bryant, {Sandra C.} and Baudhuin, {Linnea M.} and Berger, {Peter B.} and Jaffe, {Allan S}",
year = "2018",
month = "8",
day = "1",
doi = "10.1161/ATVBAHA.118.311199",
language = "English (US)",
volume = "38",
pages = "1933--1939",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Plasma Ceramides

AU - Meeusen, Jeffrey W.

AU - Donato, Leslie J.

AU - Bryant, Sandra C.

AU - Baudhuin, Linnea M.

AU - Berger, Peter B.

AU - Jaffe, Allan S

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Objective- Ceramides are sphingolipids involved with cellular signaling. Synthesis of ceramides occurs in all tissues. Ceramides accumulate within tissues and the blood plasma during metabolic dysfunction, dyslipidemia, and inflammation. Elevations of ceramides are predictive of cardiovascular mortality. We sought to verify the utility of plasma concentrations of 4 ceramides: N-palmitoyl-sphingosine [Cer(16:0)], N-stearoyl-sphingosine [Cer(18:0)], N-nervonoyl-sphingosine [Cer(24:1)], and N-lignoceroyl-sphingosine [Cer(24:0)] in predicting major adverse cardiovascular events in a diverse patient population referred for coronary angiography. Approach and Results- Plasma ceramides were measured in 495 participants before nonurgent coronary angiography. Coronary artery disease, defined as >50% stenosis in ≥1 coronary artery, was identified 265 (54%) cases. Ceramides were not significantly associated with coronary artery disease. Patients were followed for a combined primary end point of myocardial infarction, percutaneous intervention, coronary artery bypass, stroke, or death within 4 years. Ceramides were significantly predictive of outcomes after adjusting for age, sex, body mass index, hypertension, smoking, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, serum glucose, and family history of coronary artery disease. The fully adjusted per SD hazard ratios (95% confidence interval) were 1.50 (1.16-1.93) for Cer(16:0), 1.42 (1.11-1.83) for Cer(18:0), 1.43 (1.08-1.89) for Cer(24:1), and 1.58 (1.22-2.04) for the ceramide risk score. Conclusions- Elevated plasma concentrations of ceramides are independently associated with major adverse cardiovascular events in patients with and without coronary artery disease.

AB - Objective- Ceramides are sphingolipids involved with cellular signaling. Synthesis of ceramides occurs in all tissues. Ceramides accumulate within tissues and the blood plasma during metabolic dysfunction, dyslipidemia, and inflammation. Elevations of ceramides are predictive of cardiovascular mortality. We sought to verify the utility of plasma concentrations of 4 ceramides: N-palmitoyl-sphingosine [Cer(16:0)], N-stearoyl-sphingosine [Cer(18:0)], N-nervonoyl-sphingosine [Cer(24:1)], and N-lignoceroyl-sphingosine [Cer(24:0)] in predicting major adverse cardiovascular events in a diverse patient population referred for coronary angiography. Approach and Results- Plasma ceramides were measured in 495 participants before nonurgent coronary angiography. Coronary artery disease, defined as >50% stenosis in ≥1 coronary artery, was identified 265 (54%) cases. Ceramides were not significantly associated with coronary artery disease. Patients were followed for a combined primary end point of myocardial infarction, percutaneous intervention, coronary artery bypass, stroke, or death within 4 years. Ceramides were significantly predictive of outcomes after adjusting for age, sex, body mass index, hypertension, smoking, LDL (low-density lipoprotein) cholesterol, HDL (high-density lipoprotein) cholesterol, triglycerides, serum glucose, and family history of coronary artery disease. The fully adjusted per SD hazard ratios (95% confidence interval) were 1.50 (1.16-1.93) for Cer(16:0), 1.42 (1.11-1.83) for Cer(18:0), 1.43 (1.08-1.89) for Cer(24:1), and 1.58 (1.22-2.04) for the ceramide risk score. Conclusions- Elevated plasma concentrations of ceramides are independently associated with major adverse cardiovascular events in patients with and without coronary artery disease.

KW - atherosclerosis

KW - chemistry

KW - heart diseases

KW - humans

KW - laboratories

KW - metabolomics

KW - risk

UR - http://www.scopus.com/inward/record.url?scp=85052633927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052633927&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.118.311199

DO - 10.1161/ATVBAHA.118.311199

M3 - Article

C2 - 29903731

AN - SCOPUS:85052633927

VL - 38

SP - 1933

EP - 1939

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 8

ER -